Pharmacy World and Science

, Volume 20, Issue 3, pp 100–106 | Cite as

Recent developments in the management of psychosis.

  • M.J.A.J.M. Hoes


Antipsychotic drugs are effective in psychoses, whatever the aetiology of the disorder. The positive symptoms tend to respond more readily. The need for developing new drugs arises from the refractoriness of the negative symptoms, the 10‐25% of the patients that are treatment‐resistant and the problems of short‐, and long‐term extrapyramidal side‐effects. Thus far, five drugs differing from the classical antipsychotics have been licensed for use: clozapine, olanzepine, risperidone, sertindole and sulpiride, and in at least some European countries quetiapine is now in the final phase of clinical research. This review starts with a brief introduction to symptomatology, is limited to the registered drugs and addresses differences with the classical drugs in pharmacology, pharmacokinetics, clinical aspects and side‐effects. Clozapine, risperidone and sulpiride can be considered for clinical use in refractory patients, and these three together with olanzapine and sertindole are candidates when extrapyramidal side‐effects cause a clinical problem.

Antipsychotic Atypical antipsychotic Psychosis, management 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nijdam SJ. Ervaringen met moderne psychofarmaca. Den Haag: Mouton, 1966.Google Scholar
  2. 2.
    Shepherd M. Neurolepsis and the psychopharmacological revolution: myth and reality. Hist Psychiat 1994;5:89–97.Google Scholar
  3. 3.
    Hoes MJAJM. Psychofarmacotherapie: geschiedenis. Acta Neuropsychiat 1994;6:48–56.Google Scholar
  4. 4.
    Kerwin RW. The new atypical antipsychotics. Br J Psychiat 1994;164:141–9.Google Scholar
  5. 5.
    Hoes MJAJM. Klinische keuzecriteria voor antipsychotica. In: Hoes MJAJM, Nijdam SJ, Hekster YA, eds. Praktische keuzecriteria voor Psychofarmaca. Een eerstelijnshandleiding. Alphen a/d Rijn: van Zuiden Communications, 1995:13–20.Google Scholar
  6. 6.
    Hoes MJAJM. Atypische antipsychotica. GeBu 1995; 29: 23–7.Google Scholar
  7. 7.
    Beasly CM, et al. Psychopharmacol 1996; 124: 159–67.Google Scholar
  8. 8.
    Beasly CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacol 1996;14:111–23.Google Scholar
  9. 9.
    Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 1996;14:87–96.Google Scholar
  10. 10.
    Dunn ChJ, Fitton A. Sertindole. CNS Drugs 1996; Mar.5(3):224–30.Google Scholar
  11. 11.
    Kammen DP van, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacol 1996;124:168–75.Google Scholar
  12. 12.
    Casey DE. >Seroquel= (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 1996;5:939–57.Google Scholar
  13. 13.
    Fulton B, Goa KL. ICI-204,636. An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 1995;4:68–78.Google Scholar
  14. 14.
    Goldstein JM. Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 1995;4:291–8.Google Scholar
  15. 15.
    Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AHP. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacol 1993;112:S40–54.Google Scholar
  16. 16.
    DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington DC: APA, 1994.Google Scholar
  17. 17.
    Dilling H, Mombour W, Schmidt MH. Internationale Klassifikation psychischer St`rungen. ICD-10 Kapitel V (F). Bern: Huber, 1991.Google Scholar
  18. 18.
    Tiburg W van. Historische ontwikkeling van het schizofrenieconcept. In: den Boer JA, van den Bosch RJ, eds. Leerboek Schizofrenie. Een neurobiologische benadering. Utrecht: De Tijdstroom, 1996:13–42.Google Scholar
  19. 19.
    Berrios G. Delirium and cognate states. In: Berrios G, Porter R, eds. A History of Clinical Psychiatry. London: Athlone Press, 1995:13–23.Google Scholar
  20. 20.
    Kuipers Th. Stille waters.... Over de meting en beoordeling van negatieve symptomen. Utrecht: Academisch Proefschrift, 1992.Google Scholar
  21. 21.
    Andreasen NC. Negative symptoms in schoziphrenia: definition and reliability. Arch Gen Psychiat 1982;39:784–9.Google Scholar
  22. 22.
    Kay SR. Positive and negative syndromes in schizophrenia. In: van Praag HM, ed. Clinical and Experimental Psychiatry Monograph 5. New York: Brunner/Mazel, 1991.Google Scholar
  23. 23.
    Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. New Engl J Med 1991;324:746–54.Google Scholar
  24. 24.
    Angst J, Bech P, Bobon D, et al. Report on the third consensus conference on the methodology of clinical trials with antipsychotic drugs. Pharmacopsychiat 1991;24:149–52.Google Scholar
  25. 25.
    Long-term management of people with psychotic disorders in the community. Drug Ther Bull 1994;32:73–7.Google Scholar
  26. 26.
    Stolk PJ. Een historische schande. Ned Tijdschr Geneesk 1988;132:1280–2.Google Scholar
  27. 27.
    Schotte A, Lanssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo binding. Psychopharmacol 1996;124:57–73.Google Scholar
  28. 28.
    Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiat 1996;57 (suppl 11):4–11.Google Scholar
  29. 29.
    Louwerens JW, Buddingh JA, Zijlstra S, Pruim J, Korf J, Paans AMJ, Vaalburg W, Slooff CJ. Dopamine (D2) receptor occupancy in clozapine-treated patients as measured by positron emission tomography using 18FESP. In: Brunallo M, Mendlewicz J, Racagni G, eds. New Generation of Antipsychotic Drugs: Novel Mechanism of Action. Biomed Drug Res 1993;4:130–5.Google Scholar
  30. 30.
    Jenner P. The mode of action of neuroleptic drugs. In: Gorrod JW, Gibson GG, Mitchard, et al., eds. Development of Drugs and modern Medicine: a conference in honour of Prof. AH Beckett. Chichester: VHC, 1986:117–32.Google Scholar
  31. 31.
    Wagstaff AJ, Fitton A, Benfield P. Sulpiride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in schizophrenia. CNS Drugs 1994;2; 313–33.Google Scholar
  32. 32.
    Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiat 1994; 151:825–35.Google Scholar
  33. 33.
    Den Boer JA. Risperidon. Acta Neuropsychiat 1995;7:84–94.Google Scholar
  34. 34.
    Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multicentre, doubleblind, parallel-group study versus haloperidol. Br J Psychiat 1995; 166: 712–26.Google Scholar
  35. 35.
    Couinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25–40.Google Scholar
  36. 36.
    Huttunen MO, Piepponen T, Rantanen H, et al. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiat Scand 1995:91:271–7.Google Scholar
  37. 37.
    Bondolfi G, Baumann P, Patris M, et al. A randomized doubleblind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia. Venice: 8th ECNP congress, 1995: abstract.Google Scholar
  38. 38.
    Justin-Besançon L. Die Benzamide-Entdeckung und Entwicklung in der Psychiatrie. In: Linde OK, ed. Pharmakopsychiatrie im Wandel der Zeit. Klingenmünster: Tilia, 1988:349–71.Google Scholar
  39. 39.
    Marder SR, van Putten Th. Who should receive clozapine? Arch Gen Psychiat 1988;45:865–7.Google Scholar
  40. 40.
    Schooler NR. Negative symptoms in schizophrenia: assessment of the effect of risperidone. J Clin Psychiat 1994; 55 (5, suppl):22–8.Google Scholar
  41. 41.
    Selten J-PJC. Neurolepsie en akinesie. Tijdschr Psychiat 1991;33:62–5.Google Scholar
  42. 42.
    Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a metaanalysis. Int Clin Psychopharmacol 1995;10:207–13.Google Scholar
  43. 43.
    Zombroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Bruce BS, Wallin BA, Kashkin KB and the Sertindole Study Group. Controlled dose, response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiat 1997;154:782–91.Google Scholar
  44. 44.
    Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozaril study group. Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiat 1988;45:789–96.Google Scholar
  45. 45.
    Pickar D, Owen R, Litman RE, Konicki E, Guttierez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiat 1992;49:345–53Google Scholar
  46. 46.
    Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiat 1992;160 (suppl 17):41–6.Google Scholar
  47. 47.
    Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Comm Psychiat 1990;41:882–5.Google Scholar
  48. 48.
    Revicki DA, Luce BR, Weschler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Comm Psychiat 1990;41:850–4.Google Scholar
  49. 49.
    Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic in-patients: a multi-centre, double-blind comparative study. Acta Psychiat Scand 1992;85:295–305.Google Scholar
  50. 50.
    Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chonic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917–26.Google Scholar
  51. 51.
    Lindstrom LH. The effect of long-term treatment clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiat Scand 1988;77:524–9.Google Scholar
  52. 52.
    Lindström E, Eriksson B, Hellgren A, et al. Efficacy of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17:402–12.Google Scholar
  53. 53.
    Möller HJ. Open study on the long-term treatment of chronic schizophrenic patients with risperidone. Analysis of efficacy and safety data. Beerse: Janssen Research Foundation, 1993, data on file.Google Scholar
  54. 54.
    Van Alphen EEM, Kuipers T. Farmacotherapie bij een postpsychotische depressie. GeBu 1996;30:137–41.Google Scholar
  55. 55.
    Jann MW, Grimsley SR, Gray EC, Chang W-H. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokin 1993;24:161–75.Google Scholar
  56. 56.
    Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiat 1996;57 (suppl 11):12–25.Google Scholar
  57. 57.
    Levy G. A pharmacokinetic perspective on medication noncompliance. Clin Pharmacol Ther 1993;54:42–5.Google Scholar
  58. 58.
    Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 1988;8:52–6S.Google Scholar
  59. 59.
    Anderson ES, Powers PS. Neuroleptic malignant syndrome associated with clozapine use. J Clin Psychiat 1991;52:102–5.Google Scholar
  60. 60.
    Prikbord. Agranulocytosis. GeBu 1991;25:10.Google Scholar
  61. 61.
    Prikbord. Risperidon. Gebu 1994;28:94.Google Scholar
  62. 62.
    Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapineinduced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995;15:365–71.Google Scholar
  63. 63.
    Webster P, Wijeratne Ch. Risperidone-induced neuroleptic malignant syndrome. Lancet 1994;344:1228–9.Google Scholar
  64. 64.
    Grant S, Filton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994;48:253–73.Google Scholar
  65. 65.
    Ford B, Lynch T, Greene P. Risperidone for Parkinson's disease. Lancet 1994;344:681.Google Scholar
  66. 66.
    Meco G, Alessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levo-dopa-treated Parkinson's disease. Lancet 1994;344:681.Google Scholar
  67. 67.
    Singh AN, Catalan J. Risperidone in HIV-related manic psychosis. Lancet 1994;344:1029–30.Google Scholar
  68. 68.
    Preskorn SH. Reducing the risk of drug-drug interactions: a goal of rational drug development. J Clin Psychiat 1996;57:3–7.Google Scholar
  69. 69.
    Nemeroff ChB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiat 1996;153:311–20.Google Scholar
  70. 70.
    Chen S, Chou W-H, Blouin RA, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60:522–35.Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • M.J.A.J.M. Hoes
    • 1
  1. 1.Department Of PsychiatryZiekenhuis RivierenlandTielThe Netherlands

Personalised recommendations